LORUS THERAPEUTICS INC.

Patent Applications and Registrations

Patent applications and USPTO patent grants for LORUS THERAPEUTICS INC..The latest application filed is for "use of interleukin 17e for the treatment of cancer".

Company Profile

0.10.10

LORUS THERAPEUTICS INC. - CA CA
Lorus Therapeutics Inc. - Toronto CA
Lorus Therapeutics Inc. - Ontario CA
Lorus Therapeutics Inc. - 2 Meridian Road Toronto, Ontario CA
Lorus Therapeutics Inc. -
Lorus Therapeutics Inc. - Markham CA
Lorus Therapeutics Inc. - Scarborough CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer Grant 9,309,247 - Lee , et al. April 12, 2	2016-04-12
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Grant 8,394,815 - Al-Qawasmeh , et al. March 12, 2	2013-03-12
Use of interleukin 17E for the treatment of cancer Grant 8,287,851 - Wright , et al. October 16, 2	2012-10-16
2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer Grant 8,148,392 - Huesca , et al. April 3, 2	2012-04-03
Use Of Interleukin 17e For The Treatment Of Cancer App 20110158936 - Wright; Jim A. ; et al.	2011-06-30
Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in the treatment of cancer Grant 7,968,526 - Wright , et al. June 28, 2	2011-06-28
2,4,5-trisubstituted Imidazoles And Their Use As Anti-microbial Agents App 20110152337 - AL-QAWASMEH; RAED H. ; et al.	2011-06-23
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Grant 7,884,120 - Al-Qawasmeh , et al. February 8, 2	2011-02-08
Small Interfering Rna Molecules Against Ribonucleotide Reductase And Uses Thereof App 20100204305 - YOUNG; Aiping H. ; et al.	2010-08-12
Antisense Oligonucleotides Directed to Ribonucleotide Reductase R2 and Uses Thereof in the Treatment of Cancer App 20100197766 - WRIGHT; Jim A. ; et al.	2010-08-05
Antisense Oligonucleotides Directed to Ribonucleotide Reductase R2 and uses Thereof in the Treatment of Cancer App 20090118205 - WRIGHT; Jim ; et al.	2009-05-07
Immunomodulating compositions from bile App 20080279957 - Rang; Romeo	2008-11-13
Aryl imidazoles and their use as anti-cancer agents App 20080262015 - Huesca; Mario ; et al.	2008-10-23
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase Grant 7,405,205 - Wright , et al. July 29, 2	2008-07-29
Aryl imidazoles and their use as anti-cancer agents App 20070123553 - Huesca; Mario ; et al.	2007-05-31
Biological response modifier for the treatment of cancer App 20050192443 - Young, Aiping H.	2005-09-01
Immunomodulating compositions from bile App 20040101569 - Rang, Romeo	2004-05-27
Immunomodulating compositions for treatment of immune system disorders Grant 6,596,319 - Rang , et al. July 22, 2	2003-07-22
Immunomodulating compositions from bile Grant 6,551,623 - Rang April 22, 2	2003-04-22
Immunomodulating compositions from bile Grant 6,280,774 - Rang August 28, 2	2001-08-28

Company Registrations

NCAGE Code	L6432	LORUS THERAPEUTICS INC
CAGE Code	L6432	LORUS THERAPEUTICS INC

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.